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Purpose: The goal of this study was to determine
cardiovascular disease (CVD) risk associated with
familial hypercholesterolemia (FH).
Methods: A systematic review of the published
literature was conducted. All publications describing
FH risk from PubMed (“cardiovascular disease risk þ
familial hypercholesterolaemia,” 2004–2015), Inter-
net and Medline search of FH registries, and associ-
ated references were screened for FH-related CVD risk
in titles, abstracts, and study methods. CVD risk
expressed as rates, odds, or ratios of mortality and
morbidity were extracted. Each article was reviewed
for bias by 2 reviewers within 17 items in 7 categories;
a modiﬁed Newcastle-Ottawa assessment scale was
used for nonrandomized studies.
Findings: The complete literature search identiﬁed
712 potential publications: 549 from PubMed (Med-
line), 150 from registries, and 13 from references.
Fourteen articles met the inclusion criteria: 8 from
registries in the United Kingdom, the Netherlands,
Norway, and Spain; 5 from single hospitals or families
in Japan, Denmark, the Netherlands, and the United
Kingdom; and a population survey in Denmark. Across
studies, attrition bias was low in 22 (80%) of 28 items.
Risk of selection bias was high in 35 (63%) of 56
items. Selection bias risk was due to low representa-
tiveness and lack of a non-FH comparator group
within the same study; detection bias risk was due to
variable deﬁnitions of CVD outcomes/measurement;
and performance bias risk was due to long-term,
intensive treatment, the most common limitations for
registries. Studies from single hospitals and families1696lacked generalizability. In contrast, the Danish study
revealed a low bias in each of the 4 selection bias
criteria and 2 attrition risk criteria. Fatal and nonfatal
CVD events were collected in the study. Comparing
patients with FH versus non-FH patients, the odds
ratios for coronary artery disease were 10.3 (95% CI,
7.8–13.8) and 13.2 (95% CI, 10.0–17.4) in subjects
treated and not treated with lipid-lowering therapy,
respectively. These ratios fall within the ranges of ratios
reported in other studies but are generally higher than
the ratios from registries and clinics, in which intensive
specialized management is available.
Implications: There is a lack of available data
describing CVD risk in patients with FH, and many
of the existing studies have biases in their design that
could affect their risk estimates. A Danish study had
the highest quality based on a predeﬁned quality check
list, providing the most credible estimates of the
increase in CVD risk in patients with FH. The CVD
risk due to FH is high and represents unmet medical
need for patients with FH. Further research is war-
ranted to validate the magnitude of risk. (Clin Ther.
2016;38:1696–1709) & 2016 The Authors. Published
by Elsevier HS Journals, Inc.
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Familial hypercholesterolaemia (FH) is a genetic dis-
order characterized by autosomal inheritance in genes
related to LDL-C metabolism, which results in lifelong
elevation of LDL-C. More than 1500 mutations have
been identiﬁed in the LDL receptor gene (LDLR), as
well as mutations in other genes leading the clinical
FH phenotype.1
The major clinical manifestation of FH results from
the prolonged exposure of the vasculature to high
levels of LDL-C, which leads to the development
of atherosclerotic lesions in the heart, brain, and
peripheral arteries.2 These lesions in the arterial wall
gradually progress in size, occupying an increasing
proportion of the arterial lumen over time. This
scenario in turn results in restriction of blood ﬂow,
with clinical symptoms of ischemia, such as angina,
developing when Z70% obstruction occurs.3
However, most acute complications, such as
myocardial infarction (MI) and sudden cardiac
death, occur in lesions that are not severely
obstructed, and the ﬁrst manifestation of coronary
disease is often sudden death or nonfatal MI in one
half of men and women. These events occur at a
higher frequency and at an earlier age in patients with
FH than in patients without FH or patients with
polygenetic causes of elevated LDL-C.4
The risk of cardiovascular disease (CVD) is affected
by additional risk factors, including obesity, diabetes,
smoking, hypertension, male sex, and age, as well as
risk factors that are in addition to the risk associated
with increased LDL-C in both FH patients and non-
FH patients.1 The interaction of these additional risk
factors in FH compared with non-FH patients is not
well understood or studied.
The genetic mutation leading to FH is present at
birth with the increased level of LDL-C being asymp-
tomatic until the occurrence of end-organ damage.
Hence, patients can come to the attention of the health
care system through the development of end-organ
damage, the serendipitous performance of a LDL-C
measurement, or an active screening program, in
which individuals are generally targeted for screening
because of a family association or a general
population-level screening program.5 Early
management and primary CVD prevention, with
aggressive treatment of LDL-C levels with lipid-
modifying therapy and modiﬁcation of other risk
factors, have been found to be effective.6 TheJuly 2016effectiveness of primary prevention has led to the
introduction of screening programs in some countries
and a call for increased awareness by the European
Society of Cardiology.7 Screening uses clinical criteria
for FH, and no genetic mutations are identiﬁed
in many patients who have a clinical phenotype of
FH.8
Estimating the absolute increase in cardiovascular
risk resulting from FH is complicated. Case ascertain-
ment is likely to be biased toward patients experienc-
ing symptoms and cardiovascular events. When FH is
identiﬁed, modiﬁcation of risk factors, particularly
LDL-C, will reduce the risk of cardiovascular events.
Recent evidence has also demonstrated an increased
risk of raised concentrations of the LDL-like particle
plasma lipoprotein(a).9 Comparison populations will
likely be diluted by unidentiﬁed patients with FH,
leading to an overestimation of cardiovascular risk in
the comparison group. Prevalence of risk factors such
as smoking, obesity, and hypertension, as well as their
management and impact, will also likely differ
between patients with FH and the general
population, adding further complexity to calculating
the absolute risk of CVD due to FH.10
The rate of increase in cardiovascular risk associ-
ated with FH is important in determining the likely
adoption of screening and primary prevention
programs for the management of FH, as well as new
therapies recently approved to better manage patients
with FH and their CV risk.11
With these complexities in mind, the goal of the
present study was to examine the literature systemati-
cally and to quantify, if possible, the excess risk of
cardiovascular disease in FH, assessing the adequacy
and availability of the evidence according to a study
quality checklist to support health technology assess-
ment decision-making.MATERIALS AND METHODS
A systematic search of the literature was undertaken
to identify studies that examined the risk of cardio-
vascular disease in FH. A Medline search using the
search string “((((Cardiovascular Disease Risk þ
Familial Hypercholesterolaemia) NOT Nursing)
AND English [Language]) NOT randomized con-
trolled trials) NOT reviews [Publication Type]” was
performed for articles published between January 1,
2004, and December 31, 2015. An additional targeted1697
Clinical Therapeuticssearch of publications from FH registries was con-
ducted for reported estimates of increased risk. The
references of these articles were then reviewed to
identify additional studies, including a prior review
conducted by Austin et al.1 Publication titles and
abstracts were screened for content, and the
resulting articles were retrieved for full-text review.
Publications that included any measure of CVD risk
(risk, rates, odds, or ratios of mortality and morbidity)
in patients with FH were the outcomes of interest of
this review. Studies were excluded if they had no CVD
risk estimate in FH or no CVD risk estimate in FH
versus non-FH. Studies were also excluded if they
were not speciﬁc to FH (using a prospective deﬁnition
of FH) or included only a subgroup of patients with
FH. Review articles and letters to the editor were also
excluded.
To measure the potential for bias of each study, we
developed a bias assessment form based on the
Cochrane Handbook report of low risk, unclear risk,
and high risk of bias.12 Because the studies within this
search were nonrandomized trials, we adapted the
Newcastle-Ottawa criteria for nonrandomized studies
to assess study quality.13 The Newcastle-Ottawa
criteria for cohort studies broadly assess how subjects
are selected, the comparability of the cohorts, and
how outcomes are assessed. These broad categories
are divided into 6 areas of potential bias: selection
bias, performance bias, detection bias, attrition bias,
confounding, and reporting bias. An additional cat-
egory of “other biases” allows for the capture of any
bias not covered by the deﬁned categories. Selection
bias assesses where eligibility criteria are explicitly
described, the selection of the eligible population from
the target population, similarities in exposed and
unexposed groups, and exclusion of participants.
Performance bias assesses the ascertainment of
exposure and outcomes, temporal sequence, and con-
current interventions or unintended exposures. Detec-
tion bias assesses the blinding of assessors, valid and
reliable measurement of exposure status and out-
comes, and exposure durations. Attribution bias
assesses missing data across exposed and unexposed
groups. Confounding bias assesses valid and reliable
measurement of confounders and controlling for
confounders. Reporting bias assesses post hoc
analyses. A worksheet with guided questions for the
reviewer provided multiple criteria to assess bias risk
with 17 individual bias assessments being made for1698each study (Table I). Data entry and descriptive
statistics for the study characteristics and bias
assessments were captured by using Microsoft Excel
2010 (Microsoft Corporation, Redmond, Washington).
The bias assessments were performed by 2
reviewers (B.W. and G.K.) independently, and recon-
ciliation of any differences occurred by mutual agree-
ment and discussion. Reviewers applied bias
assessments to studies with reference to the speciﬁc
objective of estimating the cardiovascular risk, even if
there were multiple objectives within the article and
when the primary reason for the research was for an
alternate purpose. This approach was particularly
relevant for registries in which their primary purpose
is one of patient management rather than formal risk
calculation, but bias assessment for the risk calcula-
tion remained the focus for the purposes of the present
analysis. Bias risk assessments were coded as high risk,
low risk, and unclear risk for each study by using bias
assessment criteria.RESULTS
The complete literature search identiﬁed 712 potential
publications: 549 from PubMed (Medline), 150 from
registries, and 13 from references. After title and
abstract review, 29 articles were identiﬁed as likely
to contain cardiovascular risk estimates and were
retrieved for full-text review. Of these, 14 studies
contained estimates of the rate of increased risk of
CVD in FH and are summarized in the present study
(Table II).14–27 Eight studies were based on registries
in the United Kingdom, the Netherlands, Norway,
Japan and Spain; 5 were from single hospitals or
families in Denmark, Netherlands, and United King-
dom; and 1 was based on a population survey in
Denmark (Figure 1).
Trends in risk assessment were observed by bias
type (Table I). When bias risk was examined across
the studies, selection bias was the largest potential
threat with 63% (35 of 56) of the selection bias
criteria categorized as high risk. Performance bias was
also an issue, in which 14% (6 of 42) of the criteria
were high risk and 26% (11 of 42) were unclear risk.
Unclear risk was prevalent in both detection bias and
confounding bias, with 34% (19 of 56) of the
detection bias criteria and 64% (18 of 28) of the
confounding bias criteria identiﬁed as unclear risk. In
contrast, attrition bias and confounding bias were notVolume 38 Number 7
Table I. Summary of quality/risk of bias assessment of the included studies.
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Population-survey -based studies
Benn et al (2012) 0
Registry -based studies
Mabuchiet al (1989) 6
Simon Broome Registry
(1991) 4
Simon Broome Registry
(1999) 4
Alonso et al (2000) 11
Neil et al (2008) 4
Versmissen et al (2008) 3
Besseling et al (2014) 4
Mundal et al (2014) 5
Hospital-based and family -based studies
Jansen et al (1967) 3
Slack et al (1969) 9
Sijbrands et al (2000) 2
Sijbrands et al (2000) 2
Morcschladtet al (2004) 3
High bias assessment
count× bias type 9 13 11 2 0 0 6 1 1 3 1 1 0 3 3 1 5
White ¼ low risk of bias; light grey ¼ unclear risk of bias; dark grey ¼ high risk of bias.
B. Wong et al.a concern in most studies, with 82% (23 of 28) of the
attrition bias criteria and 93% (13 of 14) of the
confounding bias identiﬁed as low risk.
Examining bias risk across study types also revealed
trends. The registry-based studies were found to have
the highest bias risk with 30% (41 of 136) of the
bias assessment criteria identiﬁed as high risk, and
another 30% (41 of 136) identiﬁed as unclear risk.
The hospital- and family-based studies were also
found to have considerable bias risk, with 22% (19
of 85) of the bias assessment criteria identiﬁed as high
risk and 29% (25/85) identiﬁed as unclear risk.
Although there was only 1 population survey-based
study, it performed well, with 13 of 14 bias assessment
criteria reported as low risk.July 2016Population Survey-based Studies
Benn et al14 examined the prevalence of FH and the
risk of CVD for patients with FH in a population of
69,016 individuals from the Danish general
population in the Copenhagen General Population
Study. This study was the only article in our review to
use a general population survey approach, and it was
the only study to have no areas of high-risk bias.
Using a general population survey of Denmark, Benn
et al applied techniques developed in the Netherlands
and widely referred to as the Dutch Lipid Clinic
Network Criteria. The criteria consider family and
clinical CVD history, physical examination ﬁndings,
and biochemical results (LDL-C) for specifying FH
diagnosis.7 They applied probabilistic diagnostic1699
Table II. Overview of population and registry-based studies identified in the literature review.
Study
Country/
Ethnicity Study Sample
CVD Risk
Measure FH Risk Estimate Exposure Group
Comparison
Group
Population survey-based studies
Benn et al
(2012)14,*
Denmark Population survey of 69,016
patients in Denmark
OR for CAD
(fatal or
nonfatal)
10.3 (7.8–13.8) LMT-treated Random sample
of Danish
population
13.2 (10.0–17.4) No LMT
Registry-based studies
Mabuchi et al
(1989)15
Japan Cohort (Konazawa Hospital)
of 527 vs Japanese
population
PMR for CHD
(fatal)
10.9 (7.95–15.03) No LMT Japanese
population
Simon Broome
Registry (1991)16
British 526 registry patients vs
England and Wales
population
SMR for CHD
(fatal)†
3.74 (1.8–6.89) Males (age 0–79 y) Population of
England and
Wales
LMT-treated
4.13 (1.34–9.64) Females (age 0–79 y)
LMT-treated
3.86 (2.1–6.39) All 0–79
LMT-treated
Simon Broome
Registry (1999)17
British 1185 registry patients (1980–
1995) vs England and
Wales population
SMR for CHD
(fatal)†
2.6 (1.7–3.8) Males (age 0–79 y) Population of
England and
Wales
LMT-treated
Alonso et al
(2008)18
Spanish 811 registry patients vs
Spanish population
% premature CVD
(nonfatal)
8.4 (21.9%/2.6%) 80% of patients on LMT Spanish
population
Neil et al
(2008)19
British Simon Broome Registry, 3413
patients vs England and
Wales population; 1980–
1991 patients
SMR for CHD
(fatal)
1.98 (1.02–3.46) Primary prevention (age
20–79 y)
Population of
England and
WalesLMT-treated
5.15 (3.35–7.64) Secondary prevention
(age 20–79 y)
LMT-treated
Simon Broome Registry, 3413
patients vs England and
Wales population; 1992–
2006 patients
SMR for CHD
(fatal)
1.03 (0.75–1.38) Primary prevention (age
20–79 y)
LMT-treated
3.88 (3.18–4.68) Secondary prevention
(age 20–79 y)
LMT-treated
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Table II. (continued).
Study
Country/
Ethnicity Study Sample
CVD Risk
Measure FH Risk Estimate Exposure Group
Comparison
Group
Versmissen et al
(2008)20
Dutch Dutch lipid clinic patients age
455 y; N ¼ 1950
HR for MI
(nonfatal)
8.7 (4.77–15.82) No LMT Rotterdam study
in the elderly,
age/sex-
matched
subgroup to FH
patients
Not taking statin for
41 mo before their
MI
1.44 (0.80–2.60) Primary prevention
LMT-treated
Besseling et al
(2014)21
Dutch High-severity FH vs low-
severity FH (deﬁning high
severity in a novel way,
using data from 1 subgroup
and applying those data to
the whole cohort).
HR for CVD
(nonfatal)
1.25 (1.05–1.51) High severity group Low severity FH
groupLMT-treated
Does not provide a risk
estimate vs non-FH
Mundal et al
(2014)22
Norway Norway Registry 4688
patients (1992–2010) vs
Norwegian population
SMR for CVD
(fatal)
2.29 (1.65–3.19) 89.1% of patients on
LMT
Norwegian
population
Hospital- and family-based studies
Jensen et al
(1967)23
Denmark Family study of 11 families
(1944–1964 vs Danish
population)
SMR (fatal) 2.88 (1.73–4.46) LMT-treated Danish
population
Slack (1969)24 British 104 patients with clinical FH
vs 41 patients with type III,
IV, or V
hyperlipoproteinemia
First MI (fatal
and nonfatal)
60% increased
risk
LMT-treated Type III, IV, or V
hyperlipopro-
teinemia
Sijbrands et al
(2000)25
Dutch Family study of 855 ﬁrst-
degree relatives vs Dutch
population
SMR (fatal) 1.34 (1.16–1.55) LMT-treated Dutch population
Sijbrands et al
(2001)26
Dutch Pedigree analysis to a single
pair of ancestors; 250
SMR (fatal) 1.32 (1.03–1.67) LMT-treated Dutch population
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1702criteria for the determination of FH with a
modiﬁcation of the Dutch Lipid Clinic Criteria, and
removed factors that were not collected. The modiﬁed
criteria could potentially underestimate the number of
deﬁnite patients with FH and have an uncertain effect
on the cardiovascular risk proﬁle of the group as a
whole. Providing a comparison group internal to the
survey rather than using an external comparison
group such as general population improved the
validity of the comparison.
The determination of outcomes is from national
patient and death registries that claim no patients are
lost to follow-up.14 The same outcome criteria are
applied to both FH and non-FH, removing the
likelihood of differential bias in outcomes
determination. There is an unclear risk of bias in
relation to whether concurrent medications or
intended exposures could have modiﬁed risk.
Although lipid-modifying therapies (LMTs) were con-
sidered within the study, these data were only col-
lected at the time the survey was completed, with no
information provided regarding LMT use at other
times or the continuity of treatment. Use of other
interventions such as diet, weight loss, and smoking
cessation could not be determined. Because these are
relatively minor inﬂuences on cardiovascular risk and
apply to both FH and non-FH groups, however, the
risk of bias is judged to be unclear. The study scored
low risk on detection bias because the outcomes were
a combination of fatal and nonfatal CVD. This
approach is preferred to measuring only fatal events,
as nonfatal events are more common and fatality from
an event can be inﬂuenced by the proximity to, and
quality of, care.
Registry-based Studies
Registries are a convenient and easily available data
source for studying the risk of FH. The methods of
recruiting patients and the comparisons made versus
the general population expose these studies to impor-
tant patient selection and ascertainment bias, con-
current interventions bias resulting from LMT, and
challenges in controlling for confounders. Eight
registry-based studies were identiﬁed in this review.
Mabuchi et al15 examined risk of coronary heart
disease in 10 homozygous and 692 heterozygous
patients from 372 families in Japan. The
investigators provided no description of how
patients were ascertained, providing a threat toVolume 38 Number 7
Records included in
final bias assessment
Full-text articles
assessed for eligibility
(n = 712)
(n = 29)
(N = 549) (n = 150)
(n = 13)
(n = 14)
Records excluded based on title and abstract
(n = 683)
Full-text articles excluded
(n = 15)
Records screened on
basis of title and
abstract
Database search
Dec 2004−Dec 2014
MEDLINE
In
cl
ud
ed
El
ig
ib
ili
ty
Sc
re
en
in
g
Id
en
tif
ic
at
io
n 
Registry search
(Internet and MEDLINE
[PubMed])
Other resources and
hand-searching
Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram for the literature
review.
B. Wong et al.generalizability. This yields a high risk of bias for
eligibility criteria, selection of population, and
comparability of groups. Detailed clinical data were
obtained from clinic records and included validated
data on nonfatal cardiovascular events only, scoring a
high risk of detection bias. The outcome was the
proportional mortality ratio for coronary heart
disease of these patients compared with that of the
Japanese population. However, the investigators
provided no details as to the source of the Japanese
population data. It is implied that all data were
collected before the availability of LMT, which is a
potential strength of the study.
Three articles in this study were based on the Simon
Broome Registry (1991,16 1999,17 and Neil et al
[2008]19). The Simon Broome Registry itself is
brieﬂy described in the 1991 article as “beginning in
1980 with patients registered by participating lipid
clinics across the UK, to which they had been referred
by either general practitioners or hospital specialists.”July 2016Patients are deﬁned as having deﬁnite FH if they have
a total cholesterol level 47.5 mmol/L and have
tendon xanthomas themselves or in ﬁrst-degree rela-
tives. There is no other description of patient ascer-
tainment methods in the publication, and this
description is referenced by all subsequent articles.
This limited methodologic description presents a
serious risk of ascertainment bias given the low
diagnosis rate in the United Kingdom, and the bias
assessment reﬂects the high risk of bias in all patient
recruitment-related criteria. Patients in the Simon
Broome Register are treated at specialized lipid clinics
but, because registry rather than clinic data are used
for the publications, there is no description of speciﬁc
LMT usage. Our expectation is that patients in the
Simon Broome Registry are managed with the best
available therapy of associated risk factors at the time
of diagnosis and that this would have the effect of
substantially reducing the risk of CVD and introduc-
ing high risk of performance bias. This effect is1703
Clinical Therapeuticsexpected to be more pronounced with longer duration
of therapy, which seems to be the case as risk
estimates in each of the successive Simon Broome
publication exhibited lower standardized mortality
ratios (SMRs) in the same patients, as well as in new
patients, over time. Neil et al19 conducted a time-
based analysis of Simon Broome Registry data before
December 1991 and after January 1992 to examine
the effect of statin availability, recording lower SMRs
in the latter group. However, the data were based on a
secular trend rather than using concurrent control
subjects, and there were certainly lipid- and risk-
mitigating strategies available before December
1991, which affects all risk estimates from this study.
Outcome data from the Simon Broome publica-
tions16,17,19 are determined from International Clas-
siﬁcation of Disease, Ninth Revision, codes from
death registries, although the accuracy of these codes
is potentially problematic. This scenario is particularly
true for the outcome of interest (death due to CVD), in
which causes of sudden death without postmortem
ﬁndings are subject to uncertainty. General population
registries will include patients with FH who are
undiagnosed and, because the undiagnosed popula-
tion in the United Kingdom is larger than the diag-
nosed, this method provides a source of unknown bias
using this comparison group and would lower the
SMR. Finally, the Simon Broome Registry data SMR
estimates are highly variable within subgroups, largely
because of very small sample sizes in many subgroups.
In the article by Neil et al,19 for example, observed
event rates are as low as 1 to 3. Thus, the random
occurrence of a single event could double or halve the
calculated SMR.
Alonso et al18 conducted a cross-sectional study on
811 patients with FH from the Spanish National FH
Register to estimate the risk factors associated with
the development of premature CVD. The investigators
compared the results from this registry with the
overall Spanish population. This article suffers from
selection and detection biases, as it does not include
patients who are not receiving LMT and has a small
sample size. Their data yield a calculated 8.4-fold
increased risk of cardiovascular risk. Some of the
limitations and bias risks relating to selection bias
described for the Simon Broome Registry studies16,17
also apply here.
Versmissen et al20 examined the efﬁcacy of statin
treatment on the risk of coronary heart disease in17042146 patients with FH recruited from 27 lipid clinics
in the Netherlands by using Dutch Lipid Network
criteria. The bias assessment shows a high degree of
selection bias in ascertaining patients by this method,
as it is possible that patients with higher severity
disease are diagnosed within specialist systems.
Mitigating this concern is the high degree of
registration of patients in the Netherlands, with its
sophisticated cascade screening programs aimed at
diagnosing all patients with FH; this program results
in the Netherlands having the highest FH diagnosis
rates. This approach is reﬂected in the unclear risk
score in the eligibility criteria category.
This study used detailed clinic data to determine
outcomes and LMT, as opposed to “registration data”
used by other studies from the Netherlands. The data
on LMT are an important strength of this study,
allowing the investigators to account for the effect of
LMT, as well as report nonfatal events as the out-
come. Risk comparison was made to patients from the
Rotterdam survey, a separate data source from the
lipid clinics and a potential source of bias. Although
the investigators undertook an age/sex case-matched
analysis, the Rotterdam study collected only MI as
an outcome, with no data on angina outcomes, and
also restricted their analysis to older patients
(age 455 years), thus limiting comparisons versus
the patients with FH. These selection and detection
biases are both study weaknesses because they reduce
CVD event risk in patients with FH. Indeed, a feature
of the CVD risk in FH is that CVD manifests at
younger ages.
Besseling et al21 analyzed a cohort of 14,283
patients to deﬁne severe heterozygous FH and to
study the cardiovascular risk factors in these
patients. All data were collected at a single time
point (cross-sectional analysis) for the FH-screening
program in the Netherlands. The investigators used
Dutch Lipid clinic data for their analysis, which has
the most comprehensive cascade screening program
and identiﬁed the largest number of patients with FH.
These authors redeﬁned FH severity in a way that is
likely to have created a group with unknown or lower
risk by applying the percentage of patients at high risk
in one age group versus all other age groups. The
authors then compared risk between the “newly
deﬁned” high-risk group versus the remaining “low-
risk group.” The effect of both methodologic decisions
is likely to produce a low risk estimate. This risk ofVolume 38 Number 7
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bias assessment and is judged as a high risk of bias, in
addition to high risks of bias in the familiar areas of
patient selection and comparability of groups that
affect other studies.
Mundal et al22 used data obtained from the
Norwegian FH registry of 4688 patients to examine
if patients with FH in the statin era still have increased
risk of premature cardiovascular mortality. Data were
recorded at the time of registration, outcomes were
determined from mortality registries, and additional
data were obtained from hospital records for the 113
patients who died; the additional data included the use
of LMT at time of death. Limitations of registry data
as previously noted also apply to this study, including
ascertainment bias and concurrent interventions bias.
The limited data on LMT from hospital records of
patients who died limit the analysis of treatment data.
It is likely that most patients were treated with statins
given the availability of these drugs during the time
period of the study (1992–2010). We expect rates
from this study to underestimate the true risk of CVD
in FH and to better reﬂect the rate among patients
treated for an extended time.
Hospital- and Family-based Studies
In this systematic review, 2 studies were identiﬁed
on the basis of hospital data and another 3 studies on
the basis of families. These methodologies are popular
for studying patients with FH because of the relative
ease of patient recruitment. However, compared with
the population survey or registry studies, these studies
have a higher degree of selection bias because patients
are identiﬁed from a select and limited population.
The studies suffer from selection bias with comparison
groups in which the comparison groups are from a
different population source.
Jensen et al23 published one of the earlier studies
that followed up 11 Danish families over time. They
reported on SMR for all-cause mortality standardized
according to age and sex. This study suffers from a
small sample size and low numbers of events within
the small sample. Also, limited information is pro-
vided on these patients and the comparison group. It
can be better viewed as a description of a case series
and experience over time within these patients.
The study by Slack24 is an early trial that describes
the investigator’s observations of a small number of
patients with type II hyperlipidemia (n ¼ 104) andJuly 2016compares their event rate with similarly selected
patients with types III, IV, and V hyperlipidemia
(n ¼ 41) recruited from several London hospitals.
The investigator provided no formal description of the
selection process for either the patients or the control
subjects, which prevents generalization of the results.
Formal bias assessment of this article is not favorable
in a number of categories, mostly driven by the case-
report nature of the publication.
Two articles by Sijbrands et al25,26 (from 2000 and
2001, respectively) are included in this review. Both of
these articles are descriptive studies of a single large
family over time and compare all-cause mortality in
patients with FH versus the Dutch population. These
articles are limited by ascertainment bias and a lack of
generalizability. In the ﬁrst study,25 the investigators
evaluated 855 ﬁrst-degree relatives of 113 patients
who have a 50% probability of being affected, and
they found that these patients are at increased risk of
premature CVD. In the second study, Sijbrands et al
examined the genealogy of 3 probands to a single pair
of ancestors in the 19th century, then all ﬁrst-degree
relatives on the transmission line, ﬁnding 412 descen-
dants, with 250 survivingZ20 years. Due to inclusion
criteria in these studies, ascertainment bias is a
concern, as are the lack of control for confounders.
Mohrschladt et al27 recruited 345 patients from a
single clinic at the Leiden University Medical Center in
the Netherlands and observed them under treatment
for 8 years to determine CVD and event and mortality
risk in statin-treated patients with FH. The investiga-
tors compared the mortality rate from CVD in these
patients versus the general population. This study has
the advantage of prospective observation with detailed
data on the patients observed. However, ascertain-
ment bias remains a concern as the patients are within
a single clinic and thus reﬂect the practice of that
speciﬁc clinic. The study is also limited by a small
patient count. The estimates in this study are based on
24 patients who died of CVD. Finally, limited infor-
mation is provided on the general population, such as
LMT use, which is likely lower compared with these
patients recruited from a clinic.DISCUSSION
We used formal assessment of study bias to determine
the least biased literature-based estimate for the
elevated risk of CVD among patients with FH. This1705
Clinical Therapeuticsapproach has resulted in the identiﬁcation of the study
by Benn et al,14 a population-level survey undertaken
in Denmark. The study reported an odds ratio of 13.2
(95% CI, 10.0–17.4) for patients with FH not receiving
LMTs and 10.3 (95% CI, 7.8–13.8) for patients with
FH receiving LMTs, compared with patients who do
not have FH and are not receiving LMT. These high
odds ratios highlight the medical need in patients with
FH and the need for strategies and interventions to
reduce their risk of CVD.
The sources of bias identiﬁed within the reviewed
studies show that bias is concentrated toward “selec-
tion bias,” resulting in higher bias potential for those
studies that did not reﬂect community or population
representativeness. Obtaining a study sample that is
both sufﬁciently sized and representative of a general
population is challenging when the target disease is
relatively uncommon and the event of interest within
the target disease is infrequent. However, selected
cohorts are more convenient and less costly to study,
and they may have the advantage of higher baseline
response and better follow-up, as occurs in regis-
tries.28 Selection bias is of such importance within
the formal bias assessment criteria that mitigation of
this bias should occur at the study design phase of
trials in which the primary objective is to ﬁnd
generalizable results.
Benn et al14 undertook a population-level study in
which the design included methods to appropriately
sample the population to avoid ascertainment bias.
The investigators used the Copenhagen General Pop-
ulation study, which selected individuals from the
national Danish Civil Registration System to reﬂect
the adult Danish population. Speciﬁc attention to, and
acknowledgement of, the risk of ascertainment bias
should be a principal study design consideration when
a population risk estimate is the study objective.
The most common source of literature-based
estimates of increased risk is registry-derived data.
Registries in all instances were national programs
designed to identify and subsequently manage patient
risk. These programs are designed to identify as many
patients as possible with the highest risk in the most
efﬁcient way, and then to manage their risk with the
best therapies available for the remainder of the
individual’s life or as long as possible. Common
methods were used to identify patients with early
CVD, ﬁnd index cases and undertake cascade family
screening, and to intensify case ﬁnding within1706specialty settings. Although these methods are efﬁcient
and proper for registries, they result in higher bias
assessments when the purpose is to understand the
magnitude of increase in cardiovascular risk.
Within the studies reviewed, the duration of FH
management was not directly studied. However,
successive publications from the Simon Broome regis-
tries in the United Kingdom have presumably used the
same initial cohort of patients augmented with addi-
tional recruitment over time. Each successive article
therefore at least partly includes patients with pro-
gressively longer durations of treatment, which could
have reduced the reported cardiovascular risk for FH
as seen in those publications.
The odds ratio reported in the study by Benn et al14
is within the range of ratios reported in other studies
but higher than the ratios seen in estimates derived from
registry studies. In particular, the risk is similar to that
calculated by Versmissen et al20 of 8.7 (4.77–15.82),
which demonstrated the least amount of bias within
the registry-derived studies. Versmissen et al used
data from the Dutch screening program, perhaps the
most successful of the global screening programs in
case ﬁnding, which mitigated selection bias to some
degree. They also used a close proximity comparisons
group for risk calculations rather than general census
data. In addition, the study by Benn et al, including
the odds ratios for increased cardiovascular risk in
patients with FH, is prominently featured in a Euro-
pean Atherosclerosis Society consensus statement
(2013)7 on guidance for clinicians to prevent
coronary heart disease in patients with FH. This
lends additional credibility to the study and its
results as representing the best available evidence
published to date, given that the only 2 studies
published after the publication of this consensus
statement (Mundal et al22 and Besseling et al21) are
shown to be limited by a high degree of selection bias
as previously described.
Early articles concerning FH were well-written,
descriptive observations of a new phenomenon within
small groups of patients or families in which it was
observed that CVD was particularly common. As
occurs in much of medicine, these case descriptions
are valuable in generating the hypothesis concerning
the increase in risk associated with FH, and indeed the
magnitude of increase in cardiovascular risk identiﬁed
in these early reports left little doubt that the increase
was genuine. Formal bias assessments of these studiesVolume 38 Number 7
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tion of the risk.
Despite the identiﬁcation of the Benn et al14 study
as having the least biased rates, there are limitations
associated with the use of data from this study. The
ascertainment of LMT use was through the primary
survey questionnaire, which asked for LMT use at
that time, but no data are provided as to the use of
LMTs over time. The study by Benn et al examined
the rate of a genetic disorder within Denmark. There
is no evidence that FH and genetic mutations found in
Denmark are different from other countries, and the
advantage of the strong methods would likely
overcome any bias associated with theoretical
differences in genetic mutations between countries. It
should be noted that Benn et al report an average
CVD risk for FH versus non-FH at a population level.
In clinical practice, there will be variation in severity
within FH subgroups, such as those with higher or
lower levels of LDL-C and other risk factors, which
are important considerations for individual patient
management.
All of the studies included in this review used
clinical criteria, rather than genetic testing. There is
therefore no distinction between homozygous and
heterozygous FH and the possibility that enrolled
patients might have polygenic hypercholesterolemia.
Benn et al29 have subsequently examined the
mutations in 98,099 participants from their general
population study and found a very high odds ratio for
4 mutations within the clinical criteria of deﬁnite and
probable FH, validating the diagnostic criteria used in
that study. Homozygous FH results in higher levels of
LDL-C and higher cardiovascular risk, which lead to
the potential of variation in results if homozygous
patients are included in analyses at variable rates.
Mitigating this possibility, and its effects on risk
estimates, is the extreme rarity of homozygous FH,
with such individuals usually coming to the attention
of the health care system.
Additional limitations of this review merit considera-
tion. We used the modiﬁed Newcastle-Ottawa criteria
for bias assessment, in which there is potential low
agreement between reviewers and authors.30 Authors
were not contacted for clariﬁcation of bias within
this project, and assessments relied solely on the
publication. Assessment of bias relied on the expertise
and training of reviewers to assign levels of risk to each
article after reading it. Bias assessments are thereforeJuly 2016subject to reviewer interpretation and sometimes
extrapolation from the writing within the publication.
Only a single study satisﬁed the majority of the
selection bias criteria by using a population data
source. There is, therefore, lack of replication of the
result in studies of the same design, and although
similar risk estimates exist in studies of different design,
this could occur by chance. Replication of these
ﬁndings in other populations would provide greater
conﬁdence in the risk estimate. Finally, it should be
noted that only publications in the English language
were considered.
The effect of associated risk factors (eg, obesity,
smoking, lifestyle choice) and their interaction with
FH compared with their effects in the general popula-
tion is not well studied within the articles reviewed.
The current advice in the management of FH is to
address all modiﬁable associated risk factors with
lifestyle changes, although the beneﬁt of this advice
is likely associated with the relative magnitude of risk
associated with these behaviors in patients with FH
compared with those with non-FH and could be
further investigated.
We have not examined the literature for the
increase in risk of other cardiovascular manifestations
in FH and have focused on cardiac morbidity and
mortality as the most recognized source of CVD. Most
of the articles in this review used “cardiovascular
death” as an end point of interest, on the assumption
that death was due to coronary artery disease,
coronary arterial occlusion, and ﬁnally MI. The risk
determined from this end point is then reported as
cardiovascular risk. The effects of accelerated athero-
sclerosis in FH, however, are not limited to the
coronary arteries. Atherosclerosis in cerebral vessels
resulting in stroke tends to occur at a later age,
whereas atherosclerosis in peripheral arteries leading
to limb ischemia is less frequently reported overall.
Both conditions are less recognized than cardio-
vascular disease in association with FH.CONCLUSIONS
There are limited available data describing CVD risk
in patients with FH, and many of the existing studies
have biases in their study design that could affect their
results. To the best of our knowledge, this review is
the ﬁrst to perform a bias assessment of studies
reporting CVD risk in patients with FH. We found1707
Clinical Therapeuticsthat the only population survey-based study in our
review (by Benn et al14) scored best for its lack of bias
as a well-conducted study, providing credible esti-
mates of the increase in CVD risk in patients with FH.
The CVD risk due to FH is high and represents unmet
medical need for patients with FH. Further research to
assess CV risk among patients with FH using best
available methods is warranted.ACKNOWLEDGMENTS
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